Alogliptin And Pioglitazone Tablet, Film Coated
Product Images NDC 45802-260

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Alogliptin And Pioglitazone (NDC 45802-260). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Padagis Israel Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Alogliptin 01)

Chemical structure diagram of Alogliptin Benzoate, one of the active ingredients in Alogliptin and Pioglitazone tablets. The diagram shows the molecular arrangement including rings and functional groups, with chiral centers indicated.*

FDA Label Image

Chemical Structure (Alogliptin 02)

Chemical structure of Alogliptin Benzoate and Pioglitazone hydrochloride, shown as a combined molecular diagram depicting atoms and bonds including the pioglitazone thiazolidinedione ring and alogliptin pyridine moiety with a hydrochloride component indicated.*

FDA Label Image

Figure 1 (Alogliptin 03)

A forest plot chart showing the pharmacokinetic interaction ratios and 90% confidence intervals for Alogliptin when coadministered with various drugs, including Metformin, Cimetidine, Warfarin, Caffeine, Pioglitazone, Glyburide, Tolbutamide, Dextromethorphan, Atorvastatin, Ethinyl Estradiol, Norethindrone, Midazolam, Digoxin, and Fexofenadine. The chart displays AUC and Cmax ratios with dosing regimens and recommendations indicating no dose adjustments needed.*

FDA Label Image

Figure 2 (Alogliptin 04)

A forest plot chart depicting pharmacokinetic interactions between alogliptin and various coadministered drugs. The chart shows the ratio and 90% confidence intervals of alogliptin's AUC and Cmax with each interacting drug, alongside recommendations indicating no dose adjustment required. Drugs evaluated include metformin, cimetidine, gemfibrozil, pioglitazone, fluconazole, ketoconazole, atorvastatin, cyclosporine, and digoxin.*

FDA Label Image

Figure 3 (Alogliptin 05)

Bar chart depicting least squares mean change in A1C (%) from baseline mean A1C values for placebo, Alogliptin alone, Pioglitazone alone, and their combination at different doses. The chart compares efficacy levels, showing greater reductions in A1C with combination therapy compared to individual drugs and placebo.*

FDA Label Image

Principal Display Panel (12.5 mg/15 mg Tablet Bottle Label)

Kaplan-Meier cumulative event probability graph comparing Alogliptin and placebo over 30 months from randomization. The graph plots the probability of the major event on the Y-axis against time in months on the X-axis. At-risk population numbers for Alogliptin and placebo groups are shown below the timeline, with a hazard ratio stated as HR = 0.96 (98% CI: 0.80 to 1.16).*

FDA Label Image

Principal Display Panel (12.5 mg/30 mg Tablet Bottle Label)

Label for Alogliptin and Pioglitazone Tablets 12.5 mg/15 mg film-coated tablets. The label includes dosage details, storage instructions, and the distributor Perrigo. The package contains 30 tablets and has a barcode and NDC 45802-238-65.*

FDA Label Image

Principal Display Panel (12.5 mg/45 mg Tablet Bottle Label)

Label for Alogliptin and Pioglitazone Tablets 12.5 mg / 30 mg film-coated tablets by Perrigo. The label includes the NDC 45802-260-65, states the package contains 30 tablets, and provides storage instructions and dispensing information. The product is for oral use and distributed by Perrigo in Allegan, Michigan.*

FDA Label Image

Principal Display Panel (25 mg/15 mg Tablet Bottle Label)

Label for Alogliptin and Pioglitazone Tablets, 12.5 mg/45 mg film-coated oral tablets. The label includes a dosage warning, storage instructions, and states the bottle contains 30 tablets. Distributed by Perrigo with a barcode and NDC 45802-304-65 indicated.*

FDA Label Image

Principal Display Panel (25 mg/30 mg Tablet Bottle Label)

Packaging label for Alogliptin and Pioglitazone Tablets, 25 mg/15 mg strength, film-coated oral tablets by Padagis Israel Pharmaceuticals Ltd. The label includes directions to dispense with a medication guide, contains 30 tablets, and shows storage instructions and barcode.*

FDA Label Image

Principal Display Panel (25 mg/45 mg Tablet Bottle Label)

Label for Alogliptin and Pioglitazone Tablets, 25 mg/30 mg, film-coated oral tablets. The label indicates a 30-tablet bottle package by Perrigo. It includes storage instructions, dosage information, and barcode, displaying that the product is Rx only.*

FDA Label Image

Alogliptin 12

Label for Alogliptin and Pioglitazone Tablets, 25 mg/45 mg, film-coated oral tablets. The label includes the NDC 45802-499-65 and states the package contains 30 tablets. It notes the product is Rx only and distributed by Perrigo. The label includes storage instructions and a caution about the bottle seal.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.